Inhibrx Biosciences (INBX) Retained Earnings (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Retained Earnings for 3 consecutive years, with -$246.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Retained Earnings fell 131.98% year-over-year to -$246.2 million; the TTM figure through Dec 2025 stood at -$246.2 million (down 131.98% YoY), while the FY2025 annual figure was -$246.2 million, down 131.98% from the prior year.
• Retained Earnings fell to -$246.2 million in Q4 2025 per INBX's latest filing, from -$213.4 million in the prior quarter.
• Across five years, Retained Earnings topped out at $657.2 million in Q4 2023 and bottomed at -$246.2 million in Q4 2025.
• Historically, Retained Earnings has averaged $45.5 million across 3 years, with a median of -$82.2 million in 2024.
• On a YoY basis, Retained Earnings climbed as much as 5.51% in 2025 and fell as far as 266.04% in 2025.
• Inhibrx Biosciences' Retained Earnings stood at $657.2 million in 2023, then sank by 116.15% to -$106.1 million in 2024, then slumped by 131.98% to -$246.2 million in 2025.
• Business Quant data shows INBX's Retained Earnings at -$246.2 million in Q4 2025, -$213.4 million in Q3 2025, and $246.7 million in Q2 2025.